Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism

被引:41
作者
Chen, Jianguang [1 ]
Fiskus, Warren [1 ]
Eaton, Kelly [1 ]
Fernandez, Pravina [1 ]
Wang, Yongchao [1 ]
Rao, Rekha [1 ]
Lee, Pearl [1 ]
Joshi, Rajeshree [1 ]
Yang, Yonghua [1 ]
Kolhe, Ravindra [1 ]
Balusu, Ramesh [1 ]
Chappa, Prasanthi [1 ]
Natarajan, Kavita [1 ]
Jillella, Anand [1 ]
Atadja, Peter [2 ]
Bhalla, Kapil N. [1 ]
机构
[1] Med Coll Georgia, Ctr Canc, Augusta, GA 30912 USA
[2] Novartis Inst Biomed Res, Cambridge, MA USA
关键词
HISTONE DEACETYLASE INHIBITORS; ORPHAN STEROID-RECEPTOR; ACUTE MYELOID-LEUKEMIA; CYTOCHROME-C RELEASE; NEGATIVE SELECTION; CANCER CELLS; APOPTOSIS; NUR77; VORINOSTAT; EXPRESSION;
D O I
10.1182/blood-2008-08-176024
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pan-histone deacetylase inhibitors, for example, vorinostat and panobinostat (LBH589; Novartis Pharmaceuticals, East Hanover, NJ), have shown clinical efficacy against advanced cutaneous T-cell lymphoma (CTCL). However, the molecular basis of this activity remains unclear. HDAC7, a class IIA histone deacetylase (HDAC), is overexpressed in thymocytes, where it represses expression of the proapoptotic nuclear orphan receptor Nur77. Here, we demonstrate that treatment with panobinostat rapidly inhibits the in vitro and intracellular activity, as well as the mRNA and protein levels of HDAC7, and induces expression and translocation of Nur77 to the mitochondria. There, Nur77 converts death resistance protein Bcl-2 into a killer protein, promoting cell death of cultured and patient-derived human CTCL cells. Treatment with panobinostat improved survival of athymic nude mice implanted with human CTCL cells. Ectopic expression of Nur77 induced apoptosis and sensitized HH cells to panobinostat, whereas combined knockdown of Nur77 and its family member Nor1 was necessary to inhibit panobinostat-induced apoptosis of CTCL cells. Cotreatment with the Bcl-2/Bcl-x(L) antagonist ABT-737 decreased resistance and synergistically induced apoptosis of human CTCL cells. These findings mechanistically implicate HDAC7 and Nur77 in sensitizing human CTCL cells to panobinostat as well as suggest that cotreatment with an anti Bcl-2 agent would augment the anti-CTCL activity of panobinostat. (Blood. 2009;113:4038-4048)
引用
收藏
页码:4038 / 4048
页数:11
相关论文
共 51 条
[1]  
CALNAN BJ, 1995, IMMUNITY, V3, P273
[2]   Functional redundancy of the Nur77 and Nor-1 orphan steroid receptors in T-cell apoptosis [J].
Cheng, LEC ;
Chan, FKM ;
Cado, D ;
Winoto, A .
EMBO JOURNAL, 1997, 16 (08) :1865-1875
[3]  
CHOU TC, 1984, ADV ENZYME REGUL, V22, P7
[4]   HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis [J].
Dequiedt, F ;
Kasler, H ;
Fischle, W ;
Kiermer, V ;
Weinstein, M ;
Herndier, BG ;
Verdin, E .
IMMUNITY, 2003, 18 (05) :687-698
[5]   Phosphorylation of histone deacetylase 7 by protein kinase D mediates T cell receptor-induced Nur77 expression and apoptosis [J].
Dequiedt, F ;
Van Lint, J ;
Lecomte, E ;
Van Duppen, V ;
Seufferlein, T ;
Vandenheede, JR ;
Wattiez, R ;
Kettmann, R .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 201 (05) :793-804
[6]   Histone deacetylase inhibitors selectively suppress expression of HDAC7 [J].
Dokmanovic, Milos ;
Perez, Gisela ;
Xu, Weisheng ;
Ngo, Lang ;
Clarke, Cathy ;
Parmigiani, Raphael B. ;
Marks, Paul A. .
MOLECULAR CANCER THERAPEUTICS, 2007, 6 (09) :2525-2534
[7]   Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma, (CTCL) [J].
Duvic, Madeleine ;
Talpur, Rakshandra ;
Ni, Xiao ;
Zhang, Chunlei ;
Hazarika, Parul ;
Kelly, Cecilia ;
Chiao, Judy H. ;
Reilly, John F. ;
Ricker, Justin L. ;
Richon, Victoria M. ;
Frankel, Stanley R. .
BLOOD, 2007, 109 (01) :31-39
[8]   Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells [J].
Edwards, Arthur ;
Li, Jiannong ;
Atadja, Peter ;
Bhalla, Kapil ;
Haura, Eric B. .
MOLECULAR CANCER THERAPEUTICS, 2007, 6 (09) :2515-2524
[9]   Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma [J].
Ellis, Leigh ;
Pan, Yan ;
Smyth, Gordon K. ;
George, Daniel J. ;
McCormack, Chris ;
Williams-Truax, Roxanne ;
Mita, Monica ;
Beck, Joachim ;
Burris, Howard ;
Ryan, Gail ;
Atadja, Peter ;
Butterfoss, Dale ;
Dugan, Margaret ;
Culver, Kenneth ;
Johnstone, Ricky W. ;
Prince, H. Miles .
CLINICAL CANCER RESEARCH, 2008, 14 (14) :4500-4510
[10]   Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma [J].
Fantin, Valeria R. ;
Loboda, Andrey ;
Paweletz, Cloud P. ;
Hendrickson, Ronald C. ;
Pierce, Jacqueline W. ;
Roth, Jennifer A. ;
Li, Lixia ;
Gooden, Frank ;
Korenchuk, Susan ;
Hou, Xiaoli S. ;
Harrington, Elizabeth A. ;
Randolph, Sophia ;
Reilly, John F. ;
Ware, Christopher M. ;
Kadin, Marshall E. ;
Frankel, Stanley R. ;
Richon, Victoria M. .
CANCER RESEARCH, 2008, 68 (10) :3785-3794